443913-73-3 Vandetanib AKSci J95145
 
 
Loading Please Wait...
  J95145    
Vandetanib
, 95%
 
Zactima, ZD6474

Structure N/A

IDENTITY
CAS Number:443913-73-3
MDL Number:MFCD07772346
MF:C22H24BrFN4O2
MW:475.35
SPECIFICATIONS & PROPERTIES
Purity:95%
Physical Form:White to off-white to yellow powder
Melting Point:234-243°C
Long-Term Storage:Store long-term at -20°C

BIOLOGICAL INFO
Solubility:DMSO: 4mg/mL; H2O: <1mg/mL; EtOH: <1mg/mL
Application(s):VEGFR2 Inhibitor
Form:Free Base

REVIEW

 Vandetanib is an orally available receptor tyrosine kinase (RTK) inhibitor, which blocks both the vascular endothelial growth factor (VEGF) RTK and the Epidermal Growth Factor (EGF) RTK. Blockade of the VEGF receptors limits the growth of new blood vessels, which are vital to supporting the growth of tumors. Without sufficient blood supply, tumor cells become starved for nutrients, slowing or halting growth. Vandetanib is specifically indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.

REFERENCES
[1]Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. The Journal of clinical endocrinology and metabolism 2010 Jun;95(6):2664-71.
[2] Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Feb 10;28(5):767-72.
[3] Sathornsumetee S, Rich JN Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy. Drugs Today 2006 Oct;42(10):657-70.

GHS

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


Current as of March 25, 2019


Download SDS

CATEGORIES

 APIs and Bioactives > Protein Kinase Inhibitors


PubChem